🚀 VC round data is live in beta, check it out!
Neuland Laboratories Valuation Multiples
Discover revenue and EBITDA valuation multiples for Neuland Laboratories and similar public comparables like Avadel Pharmaceuticals, Aurinia Pharmaceuticals, Syndax, Ocular Therapeutix and more.
Neuland Laboratories Overview
About Neuland Laboratories
Neuland Laboratories Ltd is engaged in the manufacturing and selling of bulk drugs and caters to both the domestic and international markets. It is an API contract development and manufacturing organization (CDMO), supporting biotechnology and pharmaceutical companies in the design, development, and manufacturing of complex active pharmaceutical ingredients (APIs). The company develops small molecules and peptides for clinical trials and beyond, with the capacity to scale up through every stage of the product lifecycle to commercial manufacturing. Geographically, the group derives maximum revenue from its customers in India, followed by Europe, the USA and North America, and the Rest of the world.
Founded
1984
HQ
Employees
1.8K
Website
Sectors
Financials (LTM)
EV
$2B
Neuland Laboratories Financials
Neuland Laboratories reported last 12-month revenue of $191M and EBITDA of $47M.
In the same LTM period, Neuland Laboratories generated $119M in gross profit, $47M in EBITDA, and $29M in net income.
Revenue (LTM)
Neuland Laboratories P&L
In the most recent fiscal year, Neuland Laboratories reported revenue of $170M and EBITDA of $45M.
Neuland Laboratories expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $191M | XXX | $170M | XXX | XXX | XXX |
| Gross Profit | $119M | XXX | $73M | XXX | XXX | XXX |
| Gross Margin | 62% | XXX | 43% | XXX | XXX | XXX |
| EBITDA | $47M | XXX | $45M | XXX | XXX | XXX |
| EBITDA Margin | 25% | XXX | 26% | XXX | XXX | XXX |
| EBIT Margin | 20% | XXX | 19% | XXX | XXX | XXX |
| Net Profit | $29M | XXX | $28M | XXX | XXX | XXX |
| Net Margin | 15% | XXX | 16% | XXX | XXX | XXX |
| Net Debt | — | — | $438K | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Neuland Laboratories Stock Performance
Neuland Laboratories has current market cap of $2B, and enterprise value of $2B.
Market Cap Evolution
Neuland Laboratories' stock price is $164.45.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2B | $2B | 2.5% | XXX | XXX | XXX | $2.18 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialNeuland Laboratories Valuation Multiples
Neuland Laboratories trades at 11.1x EV/Revenue multiple, and 45.0x EV/EBITDA.
EV / Revenue (LTM)
Neuland Laboratories Financial Valuation Multiples
As of April 18, 2026, Neuland Laboratories has market cap of $2B and EV of $2B.
Equity research analysts estimate Neuland Laboratories' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Neuland Laboratories has a P/E ratio of 73.8x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV/Revenue | 11.1x | XXX | 12.5x | XXX | XXX | XXX |
| EV/EBITDA | 45.0x | XXX | 47.2x | XXX | XXX | XXX |
| EV/EBIT | 54.9x | XXX | 65.2x | XXX | XXX | XXX |
| EV/Gross Profit | 17.8x | XXX | 28.8x | XXX | XXX | XXX |
| P/E | 73.8x | XXX | 75.5x | XXX | XXX | XXX |
| EV/FCF | (655.1x) | XXX | 95.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Neuland Laboratories Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Neuland Laboratories Margins & Growth Rates
Neuland Laboratories' revenue in the last 12 month grew by 27%.
Neuland Laboratories' revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.0M for the same period.
Neuland Laboratories' rule of 40 is 55% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Neuland Laboratories' rule of X is 95% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Neuland Laboratories Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 27% | XXX | 11% | XXX | XXX | XXX |
| EBITDA Margin | 25% | XXX | 26% | XXX | XXX | XXX |
| EBITDA Growth | 53% | XXX | 2% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 55% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 95% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 2% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 2% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 0% | XXX | — | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 26% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Neuland Laboratories Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Neuland Laboratories | XXX | XXX | XXX | XXX | XXX | XXX |
| Avadel Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Aurinia Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Syndax | XXX | XXX | XXX | XXX | XXX | XXX |
| Ocular Therapeutix | XXX | XXX | XXX | XXX | XXX | XXX |
| Mesoblast | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Neuland Laboratories M&A Activity
Neuland Laboratories acquired XXX companies to date.
Last acquisition by Neuland Laboratories was on XXXXXXXX, XXXXX. Neuland Laboratories acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Neuland Laboratories
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialNeuland Laboratories Investment Activity
Neuland Laboratories invested in XXX companies to date.
Neuland Laboratories made its latest investment on XXXXXXXX, XXXXX. Neuland Laboratories invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Neuland Laboratories
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Neuland Laboratories
| When was Neuland Laboratories founded? | Neuland Laboratories was founded in 1984. |
| Where is Neuland Laboratories headquartered? | Neuland Laboratories is headquartered in India. |
| How many employees does Neuland Laboratories have? | As of today, Neuland Laboratories has over 1K employees. |
| Who is the CEO of Neuland Laboratories? | Neuland Laboratories' CEO is Davuluri Sucheth Rao. |
| Is Neuland Laboratories publicly listed? | Yes, Neuland Laboratories is a public company listed on National Stock Exchange of India. |
| What is the stock symbol of Neuland Laboratories? | Neuland Laboratories trades under NEULANDLAB ticker. |
| When did Neuland Laboratories go public? | Neuland Laboratories went public in 2008. |
| Who are competitors of Neuland Laboratories? | Neuland Laboratories main competitors are Avadel Pharmaceuticals, Aurinia Pharmaceuticals, Syndax, Ocular Therapeutix. |
| What is the current market cap of Neuland Laboratories? | Neuland Laboratories' current market cap is $2B. |
| What is the current revenue of Neuland Laboratories? | Neuland Laboratories' last 12 months revenue is $191M. |
| What is the current revenue growth of Neuland Laboratories? | Neuland Laboratories revenue growth (NTM/LTM) is 27%. |
| What is the current EV/Revenue multiple of Neuland Laboratories? | Current revenue multiple of Neuland Laboratories is 11.1x. |
| Is Neuland Laboratories profitable? | Yes, Neuland Laboratories is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Neuland Laboratories? | Neuland Laboratories' last 12 months EBITDA is $47M. |
| What is Neuland Laboratories' EBITDA margin? | Neuland Laboratories' last 12 months EBITDA margin is 25%. |
| What is the current EV/EBITDA multiple of Neuland Laboratories? | Current EBITDA multiple of Neuland Laboratories is 45.0x. |
| What is the current FCF of Neuland Laboratories? | Neuland Laboratories' last 12 months FCF is ($3M). |
| What is Neuland Laboratories' FCF margin? | Neuland Laboratories' last 12 months FCF margin is (2%). |
| What is the current EV/FCF multiple of Neuland Laboratories? | Current FCF multiple of Neuland Laboratories is (655.1x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.